Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

31 August 2024 (18:22 - 18:33)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Diego Perez de Arenaza

Italian Hospital of Buenos Aires, Buenos Aires (Argentina)

3 More presentations in this session

Presentation thumbnail

Highlights from RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure

Doctor A. Salvati (Moron, Buenos Aires, AR)

Presentation thumbnail

Highlights from Tri. fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation

Doctor J. Costabel (Buenos Aires, AR)

Presentation thumbnail

Daily Highlights by the Argentine Society of Cardiology - panel discussion

Access the full session

Session thumbnail

Daily Highlights by the Argentine Society of Cardiology

The Event

Event poster

ESC Congress 2024

31 August 2024 18:22 CET

You may be interested in

Congress Presentation

HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Congress Presentation

Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Congress Presentation

HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources